MARKET

INO

INO

Inovio Pharmaceu
NASDAQ
1.760
+0.030
+1.73%
After Hours: 1.779 +0.019 +1.10% 19:59 12/30 EST
OPEN
1.720
PREV CLOSE
1.730
HIGH
1.770
LOW
1.681
VOLUME
2.37M
TURNOVER
--
52 WEEK HIGH
2.979
52 WEEK LOW
1.300
MARKET CAP
120.92M
P/E (TTM)
-0.6682
1D
5D
1M
3M
1Y
5Y
1D
Inovio Pharmaceuticals Inc. Stock Rallies 1.7%, Outperforms Peers
Dow Jones · 5h ago
Inovio Pharmaceuticals Inc. Stock Slides 24.5%, Underperforms Peers
Dow Jones · 1d ago
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 42%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Benzinga · 1d ago
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 1d ago
Inovio Stock Sinks As FDA Pushes Back On Accelerated Approval For Rare Disease Drug
Benzinga · 1d ago
Balanced View on INOVIO’s INO-3107: Strong Long-Term Data Offset by Regulatory and Timing Uncertainty Driving Hold Rating
TipRanks · 1d ago
Inovio drops as respiratory papillomatosis asset denied accelerated review
Seeking Alpha · 1d ago
Inovio Shares Drop After FDA Says No Plans to Discuss INO-3107 Application
Dow Jones · 1d ago
More
About INO
Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from human papillomavirus (HPV)-related diseases, cancer, and infectious diseases. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation.

Webull offers Inovio Pharmaceuticals Inc stock information, including NASDAQ: INO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading INO stock methods without spending real money on the virtual paper trading platform.